# OnCo record carfilzomib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/carfilzomib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "carfilzomib" ;
  schema:name "Carfilzomib"@en ;
  schema:description "Carfilzomib is a second-generation proteasome inhibitor with less nerve damage but more heart and blood-pressure effects."@en ;
  schema:url <https://onco.cc/drugs/carfilzomib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Carfilzomib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q15366934> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Carfilzomib> ;
  onco:status "approved" ;
  onco:modality "Proteasome inhibitor (irreversible)" ;
  schema:alternateName "Kyprolis" ;
  onco:approval "US 2012: Relapsed myeloma (accelerated)", "US 2015: With lenalidomide-dexamethasone; with dexamethasone (ENDEAVOR)" ;
  onco:acceleratedApproval "US 2012-07-20: Multiple myeloma after at least 2 prior therapies including bortezomib and an immunomodulatory agent and disease progression on or within 60 days of completion of the last therapy" ;
  onco:acceleratedApprovalConfirmed "US 2016-01-21: Multiple myeloma after at least 2 prior therapies including bortezomib and an immunomodulatory agent and disease progression on or within 60 days of completion of the last therapy" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/>, <https://onco.cc/cancers/myeloma-relapsed-refractory/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:pathways <https://onco.cc/pathways/ubiquitin-proteasome-system/> ;
  onco:trials <https://onco.cc/trials/nct05438043/>, <https://onco.cc/trials/nct05572515/>, <https://onco.cc/trials/nct06152575/>, <https://onco.cc/trials/nct06158841/>, <https://onco.cc/trials/nct05552976/>, <https://onco.cc/trials/nct03989414/>, <https://onco.cc/trials/nct06892522/>, <https://onco.cc/trials/nct05704049/>, <https://onco.cc/trials/nct07227311/>, <https://onco.cc/trials/nct02899052/>, <https://onco.cc/trials/nct04973605/>, <https://onco.cc/trials/nct02773030/> .